PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Flumetasone Pivalate→

Flumetasone Pivalate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2002-29-1
Molecular formula
C27H36F2O6
Molecular weight
494.6 g/mol
Drug class
Topical glucocorticoidcorticosteroid receptor agonist
Mechanism of action
Activates intracellular glucocorticoid receptors in skin and suppresses inflammatory cytokines, leukocyte migration and immune responses, reducing erythema, oedema and pruritus.
Indications / reported uses
  • Topical treatment of corticosteroid-responsive dermatoses, including atopic dermatitis, contact dermatitis and eczema; otic formulations have separate indications for inflammatory external-ear conditions

Sources: UK product information — Flumetasone pivalate-containing products · NLM MeSH — Flumetasone · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Flumetasone Pivalate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Flumetasone Pivalate Permitted Daily Exposure (PDE) report (the Flumetasone Pivalate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Flumetasone Pivalate Occupational Exposure Limit (OEL) report (the Flumetasone Pivalate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.